Neoplasms, Cystic, Mucinous, and Serous

Neoplasms containing cyst-like formations or producing mucin or serum.

Also Known As:

Cystic Neoplasm; Mucinous Neoplasm; Neoplasm, Cystic; Neoplasm, Mucinous; Neoplasm, Serous; Serous Neoplasm; Cystic Neoplasms; Cystic, Mucinous, and Serous Neoplasms; Mucinous Neoplasms; Neoplasms, Cystic; Neoplasms, Mucinous; Neoplasms, Serous; Serous Neoplasms

Networked: 1223 relevant articles (23 outcomes, 100 trials/studies)

Relationship Network

Disease Context: Research Results

Neoplasms: 1324753
- Neoplasms by Histologic Type: 2
  - Glandular and Epithelial Neoplasms: 439
    - Neoplasms, Cystic, Mucinous, and Serous: 1223

Related Diseases

1.	Neoplasms (Cancer)
2.	Pancreatic Neoplasms (Pancreatic Cancer)
3.	Carcinoma (Carcinomatosis)
4.	Islet Cell Adenoma (Islet Cell Tumors)
5.	Pancreatic Ductal Carcinoma

Experts

1.	Hruban, Ralph H: 29 articles (09/2019 - 01/2002)
2.	Tanaka, Masao: 22 articles (01/2019 - 01/2002)
3.	Schmidt, C Max: 18 articles (02/2021 - 05/2010)
4.	Motoi, Fuyuhiko: 14 articles (04/2021 - 01/2007)
5.	Unno, Michiaki: 14 articles (03/2021 - 01/2007)
6.	Klimstra, David S: 14 articles (01/2016 - 01/2002)
7.	Salvia, Roberto: 13 articles (05/2022 - 07/2007)
8.	Wolfgang, Christopher L: 13 articles (01/2022 - 03/2010)
9.	Allen, Peter J: 12 articles (01/2022 - 11/2009)
10.	Furukawa, Toru: 12 articles (03/2021 - 01/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Neoplasms, Cystic, Mucinous, and Serous:

1.	MucinsIBA 01/01/2016 - "Biliary tract intraductal papillary mucinous neoplasm: single-operator cholangioscopy and clearance of mucin obstruction." 01/01/2016 - "The second aim of the study was to compare intraductal papillary mucinous neoplasm subtypes, which received consensus diagnoses (≥80% agreement) with their respective mucin immunoprofiles (MUC1, MUC2, MUC5AC, MUC6, and CDX2). " 12/01/2022 - "Salivary gland intraductal papillary mucinous neoplasm (SG IPMN) is a recently proposed entity characterized by a papillary-cystic proliferation of mucin-producing cells. " 12/01/2022 - "Histopathological examination revealed a low- grade appendiceal mucinous neoplasm(LAMN)accompanied by extra-appendiceal mucin extrusion due to the lack of epithelial lining. " 12/01/2022 - "[A Case of Low-Grade Appendiceal Mucinous Neoplasm with Extra-Appendiceal Mucin Extrusion Successfully Treated with Laparoscopic Surgery]."
2.	Carcinoembryonic AntigenIBA 04/01/2023 - "The present study aimed to examine the correlation between preoperative carcinoembryonic antigen levels in pancreatic juice (PJ-CEA) and the histological subtype of intraductal papillary mucinous neoplasm (IPMN). " 01/01/2017 - "The present study aimed to investigate the value of GNAS testing when added to KRAS and carcinoembryonic antigen (CEA) testing of PCF for the diagnosis of intraductal papillary mucinous neoplasms (IPMN). " 01/01/1992 - "Immunohistochemical study of carcinoembryonic antigen in mucinous cystic neoplasm of the pancreas." 04/01/2023 - "Carcinoembryonic antigen levels in pancreatic juice are associated with histological subtypes of intraductal papillary mucinous neoplasm of the pancreas." 07/14/2019 - "Carcinoembryonic antigen (CEA) and cytology in pancreatic cystic fluid are suboptimal for evaluation of pancreatic cystic neoplasms. "
3.	Gemcitabine FDA Link 07/01/2013 - "Gemcitabine in patients with intraductal papillary mucinous neoplasm with an associated invasive carcinoma of the pancreas." 07/01/2013 - "The standard chemotherapy for invasive ductal carcinoma of the pancreas (IDC) is gemcitabine; however, the efficacy of gemcitabine in invasive intraductal papillary mucinous neoplasm with an associated invasive carcinoma of the pancreas (IPMN-IC) is still unknown. " 11/01/2008 - "[Remarkable effect of gemcitabine-oxaliplatin (GEMOX) therapy in a patient with advanced metastatic mucinous cystic neoplasm of the pancreas]." 11/01/1998 - "In the clinical diagnostic arena: the World Health Organization established a standard nomenclature for intraductal papillary mucinous neoplasms, mucinous cystic tumors, intraductal mucinous hyperplasias, and solid pseudopapillary tumors; focal glandular differentiation may be commonly identified within pancreatic endocrine neoplasms (islet cell tumors) while not necessarily implying an unfavorable prognosis typical of ductal adenocarcinomas; positron emission tomography scanning may be used for evaluation of early tumor response to novel chemotherapeutic regimens; helical computed tomography (CT) is the state of the art in preoperative imaging for pancreatic cancer; neoadjuvant 5-fluorouracil (5-FU)-based chemoradiation in 39 "resectable" patients provided a median survival of 19 months, actuarial 4-year survival of 19%, and improved local tumor control; gemcitabine has shown promise in alleviating tumor-related symptoms with a significantly better "clinical benefit response" than single agent 5-FU (23.8 vs. 4.8%, p = 0.0022) based on change in pain intensity, daily analgesic consumption, performance status, and weight; a significant survival advantage was demonstrated in patients treated with conventional therapies whose tumors expressed p21WAF-1, an important inhibitor of cell cycle progression and downstream molecule of p53 and TGF-beta; a p21-adenovirus (rAD-p21) gene therapy resulted in significant growth inhibition of pancreatic cancer cell lines in tissue culture, and development of a successful SCID mouse-human pancreatic adenocarcinoma xenograft model provided an animal model for preclinical trials of rAD-p21."
4.	Ethanol (Ethyl Alcohol)IBA 05/01/2016 - "The true efficacy of EUS-guided ethanol lavage (EEL) of pancreatic cystic neoplasms is unclear. " 10/01/2023 - "EUS-guided ethanol ablation is a recently introduced treatment approach for pancreatic cystic lesions (PCLs), including branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs). " 10/01/2019 - "Malignant conversion and peritoneal dissemination after endoscopic ultrasound-guided ethanol ablation in intraductal papillary mucinous neoplasm of the pancreas." 05/01/2016 - "EUS-guided ethanol lavage does not reliably ablate pancreatic cystic neoplasms (with video)." 11/01/2008 - "Recently, ethanol ablation has been evaluated in pancreatic cystic neoplasms. "
5.	Pregnenolone Carbonitrile (PCN)IBA 04/01/2022 - "Pancreatic cystic neoplasms (PCN) management consists of non-invasive imaging studies (CT, MRI), with a high resource burden. " 12/01/2019 - "This study aims to investigate a potential intracystic pancreatic microbiome in a pancreatic cystic neoplasm (PCN) surgery patient cohort. " 04/01/2019 - "Pancreatic cystic neoplasms (PCN) are being found increasingly in imaging studies. " 01/01/2017 - "The study aims were to evaluate: (1) whether a short-protocol (SP) MRI for the surveillance of pancreatic cystic neoplasms (PCN) provides equivalent clinical information as a comprehensive-protocol (CP), and (2) the cost reduction from substituting CP with SP for patient surveillance. " 12/01/2023 - "A total of 303 patients with histologically confirmed pancreatic cystic neoplasm (PCN), including serous cystic neoplasm (SCN) and mucinous cystic neoplasm (MCN), from Shanghai Changhai Hospital between March 2011 and November 2021 were included. "
6.	Fluorouracil (Carac)FDA LinkGeneric 09/01/2023 - "If the CRS was complete, the use of EPIC 5-fluorouracil, the interval between the index CRS and the SCRS, the histologic grade of the mucinous neoplasm, and the extent of recurrent disease were prognostic variables that should be used to help select patients for SCRS." 09/01/1995 - "Nine patients with pseudomyxoma arising from mucinous neoplasms of the ovary and intestinal tract received a total of 89 courses of intraperitoneal 5-fluorouracil (IP5FU). " 11/01/1998 - "In the clinical diagnostic arena: the World Health Organization established a standard nomenclature for intraductal papillary mucinous neoplasms, mucinous cystic tumors, intraductal mucinous hyperplasias, and solid pseudopapillary tumors; focal glandular differentiation may be commonly identified within pancreatic endocrine neoplasms (islet cell tumors) while not necessarily implying an unfavorable prognosis typical of ductal adenocarcinomas; positron emission tomography scanning may be used for evaluation of early tumor response to novel chemotherapeutic regimens; helical computed tomography (CT) is the state of the art in preoperative imaging for pancreatic cancer; neoadjuvant 5-fluorouracil (5-FU)-based chemoradiation in 39 "resectable" patients provided a median survival of 19 months, actuarial 4-year survival of 19%, and improved local tumor control; gemcitabine has shown promise in alleviating tumor-related symptoms with a significantly better "clinical benefit response" than single agent 5-FU (23.8 vs. 4.8%, p = 0.0022) based on change in pain intensity, daily analgesic consumption, performance status, and weight; a significant survival advantage was demonstrated in patients treated with conventional therapies whose tumors expressed p21WAF-1, an important inhibitor of cell cycle progression and downstream molecule of p53 and TGF-beta; a p21-adenovirus (rAD-p21) gene therapy resulted in significant growth inhibition of pancreatic cancer cell lines in tissue culture, and development of a successful SCID mouse-human pancreatic adenocarcinoma xenograft model provided an animal model for preclinical trials of rAD-p21."
7.	Transforming Growth Factor beta (TGF-beta)IBA 07/01/1997 - "Different expression of transforming growth factor beta 1 in pancreatic ductal adenocarcinoma and cystic neoplasms." 11/01/1998 - "In the clinical diagnostic arena: the World Health Organization established a standard nomenclature for intraductal papillary mucinous neoplasms, mucinous cystic tumors, intraductal mucinous hyperplasias, and solid pseudopapillary tumors; focal glandular differentiation may be commonly identified within pancreatic endocrine neoplasms (islet cell tumors) while not necessarily implying an unfavorable prognosis typical of ductal adenocarcinomas; positron emission tomography scanning may be used for evaluation of early tumor response to novel chemotherapeutic regimens; helical computed tomography (CT) is the state of the art in preoperative imaging for pancreatic cancer; neoadjuvant 5-fluorouracil (5-FU)-based chemoradiation in 39 "resectable" patients provided a median survival of 19 months, actuarial 4-year survival of 19%, and improved local tumor control; gemcitabine has shown promise in alleviating tumor-related symptoms with a significantly better "clinical benefit response" than single agent 5-FU (23.8 vs. 4.8%, p = 0.0022) based on change in pain intensity, daily analgesic consumption, performance status, and weight; a significant survival advantage was demonstrated in patients treated with conventional therapies whose tumors expressed p21WAF-1, an important inhibitor of cell cycle progression and downstream molecule of p53 and TGF-beta; a p21-adenovirus (rAD-p21) gene therapy resulted in significant growth inhibition of pancreatic cancer cell lines in tissue culture, and development of a successful SCID mouse-human pancreatic adenocarcinoma xenograft model provided an animal model for preclinical trials of rAD-p21." 11/01/1998 - "Among the findings: peptic ulcer disease is a significant predisposing risk factor (odds ratio = 3.9) for pancreatic cancer; as many as 50% of all intraductal papillary mucinous neoplasms are associated with invasive adenocarcinomas; alteration of gene expression via methylation of a gene promotor region constitutes a potentially reversible method of tumor suppressor gene inactivation; > 400 transcriptional alterations of gene expression have been identified for pancreatic cancer; some common molecular markers such as p53 and HER-2/neu may be related to morphologic alterations of in situ neoplasia and to transcriptional alterations of gene expression rather than mutational events; epidermal growth factor (EGF), transforming growth factor beta (TGF-beta), and related molecules may modulate gene transcription via "autocrine" or "paracrine" mechanisms; several cytokines, amylin (islet amyloid polypeptide), and other cachexia factors are responsible for paraneoplastic peripheral insulin resistance, ineffective utilization of glucose, and profound cachexia. "
8.	Analgesics (Analgesic Drugs)IBA 11/01/1998 - "In the clinical diagnostic arena: the World Health Organization established a standard nomenclature for intraductal papillary mucinous neoplasms, mucinous cystic tumors, intraductal mucinous hyperplasias, and solid pseudopapillary tumors; focal glandular differentiation may be commonly identified within pancreatic endocrine neoplasms (islet cell tumors) while not necessarily implying an unfavorable prognosis typical of ductal adenocarcinomas; positron emission tomography scanning may be used for evaluation of early tumor response to novel chemotherapeutic regimens; helical computed tomography (CT) is the state of the art in preoperative imaging for pancreatic cancer; neoadjuvant 5-fluorouracil (5-FU)-based chemoradiation in 39 "resectable" patients provided a median survival of 19 months, actuarial 4-year survival of 19%, and improved local tumor control; gemcitabine has shown promise in alleviating tumor-related symptoms with a significantly better "clinical benefit response" than single agent 5-FU (23.8 vs. 4.8%, p = 0.0022) based on change in pain intensity, daily analgesic consumption, performance status, and weight; a significant survival advantage was demonstrated in patients treated with conventional therapies whose tumors expressed p21WAF-1, an important inhibitor of cell cycle progression and downstream molecule of p53 and TGF-beta; a p21-adenovirus (rAD-p21) gene therapy resulted in significant growth inhibition of pancreatic cancer cell lines in tissue culture, and development of a successful SCID mouse-human pancreatic adenocarcinoma xenograft model provided an animal model for preclinical trials of rAD-p21."
9.	Glycoproteins (Glycoprotein)IBA 10/01/2002 - "In contrast, PanINs, especially higher grade lesions, were often positive for MUC1 (61% of PanIN 3), whereas the expression of this glycoprotein was infrequent in intraductal papillary mucinous neoplasms (20%). " 10/18/2023 - "Cyst fluid glycoproteins accurately distinguishing malignancies of pancreatic cystic neoplasm." 03/01/2010 - "The expression of different MUC glycoproteins has helped define cellular lineage in variety of pancreatic neoplasms, and has helped identify distinct carcinogenic pathways such as the intestinal pathway characterized by diffuse/strong MUC2/CDX2 expression in intestinal-type intraductal papillary mucinous neoplasms (IPMNs) and their associated colloid carcinomas (CCs). " 11/01/2007 - "Intraductal papillary-mucinous neoplasm (IPMN) of the pancreas encompasses a spectrum of neoplasms with both morphological and immunohistochemical variations of mucin glycoproteins. " 10/01/2002 - "The findings here also support the previous impression that MUC2 (the mucin associated with gel formation) is a marker of the "indolent" pathway (intraductal papillary mucinous neoplasm and colloid carcinoma), whereas MUC1 (the glycoprotein known to have an inhibitory role in cell-cell and cell-stroma interactions as well as in immunoresistance of tumor cells) is a marker of the "aggressive" pathway (PanIN to ductal adenocarcinoma)."
10.	Paclitaxel (Taxol)FDA LinkGeneric 06/01/2014 - "Endoscopic ultrasound (EUS)-guided ethanol lavage with paclitaxel injection has been shown to be effective for the treatment of pancreatic cystic neoplasms; however, the evidence for effectiveness is based primarily on cyst resolution on imaging. "

Therapies and Procedures

1.	Pancreatectomy 01/01/2010 - "We herein report a patient with widespread intraductal papillary mucinous neoplasm treated successfully with total parenchymal pancreatectomy. " 01/01/2008 - "Noninvasive pancreatic cystic neoplasms can be safely and effectively treated by limited pancreatectomy." 01/01/2008 - "Noninvasive pancreatic cystic neoplasms can be safely and effectively treated by limited pancreatectomy." 11/01/2021 - "Robotic pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: A large-scale study." 01/01/2020 - "The purpose of this study was to assess short-term outcomes, long-term nutritional status, quality of life (QOL), and pancreas function after pancreatectomy for cystic neoplasms. "
2.	Therapeutics 02/15/2016 - "The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN)." 05/01/2023 - "Some studies have examined the effectiveness of EUS-guided injection ablation therapy for pancreatic cystic neoplasms (PCNs) and have reported CR rates that range from 35% to 79%. " 02/15/2016 - "The literature investigating pancreatic invasive intraductal papillary mucinous neoplasm (IPMN) has largely come from small institutional studies, preventing adequately powered comparisons of adjuvant therapy versus surgery alone (SA) within specific patient subgroups. " 01/01/2024 - "The feasibility of EUS-guided antitumor therapy has been reported both in pancreatic solid and cystic neoplasms, with promising preliminary results. " 10/01/2023 - "However, no clear guidelines are available regarding the oncologic effects of adjuvant therapy (AT) in resected invasive intraductal papillary mucinous neoplasms (IPMN). "
3.	Adjuvant Chemotherapy 04/01/2013 - "Adjuvant chemotherapy seems beneficial for invasive intraductal papillary mucinous neoplasms." 01/01/2019 - "Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data." 01/01/2022 - "The present systematic review aimed to compare survival outcomes of invasive intraductal papillary mucinous neoplasms (IIPMNs) treated with adjuvant chemotherapy versus surgery alone and to identify pathologic features that may predict survival benefit from adjuvant chemotherapy. " 01/01/2019 - "Very little is known about adjuvant chemotherapy for invasive Intraductal Papillary Mucinous Neoplasms (IPMNs) of the pancreas. " 01/01/2018 - "The aims of the study were to compare survival outcomes between patients with pancreatic ductal adenocarcinoma (PDAC) and invasive intraductal papillary mucinous neoplasms (IPMN) and to determine candidates for adjuvant chemotherapy. "
4.	Punctures 06/01/1994 - "CA 125, CA 19.9, CEA, MCA, E2 and P levels have been assessed in the serum and in the ovarian mass fluid of 216 patients through echo-guided puncture to distinguish between functional, benign and malignant cystic neoplasm. " 06/01/1982 - "These results indicate that experienced observers using proper technique will rarely be in error in distinguishing non-neoplastic cystic masses from cystic neoplasms by articulated-arm gray-scale ultrasonography, and that routine needle puncture may be unnecessary in such cases." 03/01/1997 - "Endosonography has become an integral part of the transmural procedure because it can help diagnose cystic neoplasms, localize pseudocysts, detect submucosal vessels, and measure the cyst to mucosal distance for transmural punctures. " 11/01/2014 - "After exclusion of other causes of cystic left supraclavicular masses including cystic neoplasms and pseudoaneurysms of the carotid or subclavian arteries, direct puncture sclerotherapy can be safe and effective. " 10/30/2013 - "After exclusion of other causes of cystic left supraclavicular masses including cystic neoplasms and pseudoaneurysms of the carotid or subclavian arteries, direct puncture sclerotherapy can be safe and effective. "
5.	Sclerotherapy 11/01/2014 - "After exclusion of other causes of cystic left supraclavicular masses including cystic neoplasms and pseudoaneurysms of the carotid or subclavian arteries, direct puncture sclerotherapy can be safe and effective. " 10/30/2013 - "After exclusion of other causes of cystic left supraclavicular masses including cystic neoplasms and pseudoaneurysms of the carotid or subclavian arteries, direct puncture sclerotherapy can be safe and effective. "